Data from a number of laboratories indicate that human platelets contain type I plasminogen activator inhibitor (PAI-1) primarily in a latent form; however, one report (Biochemistry 28:5773, 1989) indicated that it is predominantly the active form of PAL1 that is present in and can be purified from an ammonium sulfate precipitate of porcine platelets. To clarify this situation, we investigated and compared the status of PAI-1 in porcine and human platelets. Immunologic analysis of the ability of PAI-1 t o form complexes with immobilized t-PA indicated that porcine and human platelets contained 3.7 * 0.4 and 1.7 * 0.3 U of PA1 activity per lo8 platelets (n = 6; k SD), respectively; sodium dodecyl sulfate (SDS)activation of the lysates increased PAI-1 activity t o 10.8 k 3.0 and 3.8 k 0.5 U per lo8 platelets. Platelet lysates were also
treated with an excess of soluble t-PA, which formed complexes with active PAI-1, whereas the latent form was detected by SDS-polyacrylamide gel electrophoresis and reverse fibrin autography. Furthermore, immobilized t-PA was able t o deplete active PAL1 from the platelet extracts,
BNORMAL thrombus formation and dissolution are
A associated with several cardiovascular diseases including atherosclerosis and both thromboembolic and hemorrhagic conditions. Platelets play a critical role in these processes at early times during the initial formation of the platelet/fibrin hemostatic plug, and at later times in which they help to maintain the integrity of the thrombus through the release of fast-acting plasminogen activator inhibitors (PAIS).' The primary PA1 released by platelets is immunologically identical to the inhibitor produced by endothelial and is routinely referred to as type-1 PAI.7ps This molecule has been cloned and classified in the serine protease inhibitor (Serpin) s~perfamily.~,~ PAI-1 reacts rapidly against urokinase and both forms of tissue-type plasminogen activator (ie, single-and two-chain t-PA) with rate constants greater than lo7 [mol/L]-' sec-l, which results in the formation of high molecular weight, inactive PA/PAI-1 comple~es.~J The importance of PAI-1 as a key regulator of vascular fibrinolysis is provided by numerous reports associating elevated levels of PAI-1 activity and the increased tendency for thrombosis, as well as the correlation of isolated bleeding disorders with states of defective PAI-1 a~tivity.~ Current data indicate that PAI-1 is produced in an active conformation; however, this inhibitor is relatively unstable and is rapidly converted at 37°C into an inactive inhibitor?-10 A variety of denaturants (eg, guanidine, urea) are able to convert this inactive form into an active inhibitor," hence the term "latent" is commonly used to denote this denaturant-activatable form of PAI-l. [5] [6] [7] [8] [9] [10] [11] The observation that latent PAI-1 can be reactivated in vivo12 indicates that natural mechanisms exist to mediate the conversion of the latent form of PAI-1 into an active molecule. For example, negatively charged phospholipid vesicles have been found to be capable of activating latent PAI-l,I3 suggesting that negatively charged platelet surfaces, which are exposed during the aggregation of platelets, play a role in this process. Although human platelets contain PAI-1 primarily and the latent form remaining in the absorbed extract could be quantitated by activation with 4 mol/L guanidine. To investigate the differences between our observations and the published data, porcine platelets were extracted, and PAL1 was partially purified as described in the literature. For quantitative analysis, porcine platelet PAI-1 was also purified t o homogeneity using standard chromatographic procedures optimized in our laboratory for endothelial PAI-1, and the purified protein was used t o develop an enzyme-linked immunoabsorbent assay for porcine PAL1 antigen. Our results indicate that: (1) latent PAL1 in concentrated ammonium sulfate precipitates of porcine platelet lysates cannot be detected unless the precipitates are diluted before treatment with denaturants; and (2) active and latent porcine platelet PAI-1 can be separated by gel filtration over molecular sieving columns. In summary, this report documents that PAI-1 in porcine platelets is present in both an active and a latent form. 0 1992 by The American Society of Hematology.
in a latent f0rm,5,~,*~J~ one group reported that it is predominantly the active form of PAI-1 that is present in and can be purified from an ammonium sulfate precipitate of porcine pIatelets.l6 These latter data have raised the possibility that porcine platelets may represent a unique opportunity for delineating the mechanism(s) that mediate the conversion of latent PAI-1 into a fully active inhibitor. In light of this possibility, we initiated an in-depth study of the status of PAI-1 in porcine platelet lysates.
MATERIALS AND METHODS
Fibrinolytic proteins. t-PA purified from Bowes melanoma cell line was obtained from American Diagnostica Inc (Greenwich, CT). The specific activity of sct-PA used was 500,000 IU/mg when compared in a chromogenic assay against the t-PA International standard (National Institute for Biological Standards and Controls [NIBSC]; London, Great Britain; Ref No. 83/517). Human PAL1 was purified from the media conditioned by a transformed human lung fibroblast cell line (SVa W138 VA132 RA), and antiserum to purified PAI-1 was raised in New Zealand rabbits according to procedures described previo~sly.'~ Affinity purification of the rabbit antihuman PAI-1 antibody was performed as described.'* In brief, PAL1 was coupled to CNBr-activated Sepharose 4B (Pharmacia LKB Biotechnology Inc, Piscataway, NJ) according to the manufacturer's instructions. The IgG fraction of rabbit antisera to PAI-1 was isolated, and 100 mg of IgG was circulated (16 hours, 4°C) through the PAI-1-Sepharose column at 10 mL/h. The column was washed with phosphate-buffered saline (PBS), and then eluted with 0.2 mol/L glycine-HC1, pH 2.5. The eluted antibodies were immediately neutralized with 1 mol/L Tris-HC1, pH 8.1. Protein was determined by the BCA assay (Pierce, Rockford, IL). For the biotinylation of the affinity purified antibody, ImmunoPure NHS-LC-Biotin (Pierce) was used according to the manufacturer's instructions.
Porcine blood was collected from two groups of pigs. In the first group, whole blood from anesthetized, untreated, healthy domestic pigs (800 mL/pig; n = 10) was collected into acid citrate dextrose (ACD) (0.025 mol/L citric acid, 0.85 mol/L sodium citrate, 2% dextrose; one part ACD, five parts whole blood) using an axillary catheter. Following withdrawal of the blood, this group of pigs would serve in a separate study as organ donors for the recovery of pulmonary macrophages. In the second group, blood (20 to 30 mL, n = 20) was withdrawn from lightly restrained pigs via an axillary vein catheter before injection of a compound. This latter group of animals was to be subsequently used in a study evaluating the hemodynamic effects of a series of plasma expanders. Platelet-rich plasma (PRP) was prepared by centrifugation of anticoagulated whole blood (200g x 15 minutes). The PRP was aspirated without agitating the buRy coat and centrifuged (2,500g x 15 minutes). The platelet pellet was washed twice with 0.2 mol/L Tris-HCl, 0.15 mol/L NaCl, and 2.5 mmol/L EDTA, pH 7.5. Unless otherwise indicated, the resultant pellet was resuspended to a final concentration of lo9 platelets/mL and frozen at -70°C until used. The platelets were lysed either with 0.2% Triton X-100 (Sigma Chemical Co, St Louis, MO) or by repeated freezing and thawing cycles. Alternatively, to rule out possible effects of repeated freezing and thawing on the activity status of PAI-1, purification experiments were repeated using fresh platelets immediately after their harvest from the PRP. In a separate series of experiments, platelets were diluted into 50 mmol/L arginine-HC1, pH 7.4,19 and frozen at -80°C until used.
Human PRP was prepared by collecting blood from the antecubital vein of six healthy individuals into 5 vol ACD followed by centrifugation (200g x 15 minutes). Platelets were isolated from the PRP and frozen at -80°C as described above.
The procedures described by Fay and Owen16 were modified to include: (1) the use of fresh (ie, not frozen and thawed) platelets; and (2) a modification of volume scale to permit the partial purification of porcine platelet PAI-1 to be performed on an analytical scale. Basically, fresh porcine platelets (lo9 platelets/mL, 25 mL) were harvested and immediately diluted with 4 vol of 0.02 mol/L Tris-HCl, 0.05% p-mercaptoethanol (BME), 0.01% Tween 80,O.Z mmol/L EDTA, and 50 KIU/mL aprotinin (Calbiochem, Inc, La Jolla, CA), pH 8.0. This and all subsequent steps were performed at 4°C. The mixture was stirred slowly for 12 hours and the suspension was centrifuged (10,OOOg x 20 minutes). The supernatant was brought to 40% saturation with ammonium sulfate, stirred for 30 minutes, and centrifuged (13,00$ x 20 minutes). The supernatant was brought to 65% ammonium sulfate saturation, stirred for 30 minutes, and centrifuged as before. The pellet was dissolved in a minimal volume (2 mL) of 0.02 mol/L Tris-HC1, 0.5 mol/L NaCl, 0.01% Tween 80, 0.05% BME, 0.2 mmol/L EDTA, and 50 KIU/mL aprotinin, pH 8.0 (gel filtration buffer). This crude ammonium sulfate platelet extract was incubated with 0.1% dithiothreitol for 2 hours and clarified by centrifugation (20,OOOg x 10 minutes). The supernatant was fractionated on a Preparation of platelets.
Partial purification of PAI-I from porcine platelets.
column of Sephacryl S-200 (1.8 x 120 cm; Pharmacia) that was eluted at 13.5 mL/h with gel filtration buffer. Fractions (2.1 mL) were collected and assayed for active and denaturant-activatable PAI-1 as described below. Blue Dextran 2000 (2 x lo6 daltons), bovine serum albumin (BSA) (67,000 daltons), and ribonuclease A (13,700 daltons) (all obtained from Pharmacia) were used to calibrate the column. Experiments were also performed with pools of porcine platelets that were frozen and thawed (5 x lo9 platelets/ mL, 8 mL), yielding similar results as obtained with fresh porcine platelets.
To obtain data on the specific activity of porcine PAI-1, it was purified from porcine platelets using a procedure that had been optimized for the purification of PAI-1 from bovine and human endothelial cell-conditioned medium. In brief, platelets were lysed by repeated freezing and thawing cycles (approximately 20 mL of lo9 plateletslml), centrifuged, and mixed overnight (4°C) with 20 mL of concanavalin A Sepharose that had been previously equilibrated with TBS (0.01 mol/L Tris, pH 8.1, 0.14 mol/L NaCl, 0.01% Tween 80, 1 mmol/L CaC12, 1 mmol/L MgC12). The slurry was poured into a column (25 x 1 cm), washed with TBS and eluted with high salt buffer (0.01 mol/L Tris, pH 8.1, 0.01% Tween 80, 1 mmol/L CaC12, 1 mmol/L MgC12,0.5 mol/L a-methyl-d-mannoside, 1 mol/L NaCl). The eluate was passed over a lysine-Sepharose column (10 x 1 cm) that had been equilibrated overnight with TBS and absorbed onto a hydroxylapatite column. Protein was eluted from the hydroxylapatite column with a stepwise gradient of sodium phosphate (0.01 mol/L Nap04 to 0.13 mol/L NaP04), and the PAI-l-containing fractions were pooled and concentrated on an Amicon 10 YMlO (Amicon Corp, Danvers, MA) 25-mm filtration membrane. The concentrate was further purified by gel filtration on a Sephacryl $200 column (120 x 1.8 cm; Pharmacia) in 0.1 mol/L ammonium bicarbonate buffer. Sodium dodecyl sulfate-polyacrylamide gel electrophoresis (SDS-PAGE) of the final product showed a single molecular weight (M,) 46-Kd band when analyzed either by silver staining or by immunoblotting with rabbit antihuman PAI-1 using previously described protocol^.^^ Purified porcine PAL1 was used as a calibration standard in the analysis of porcine platelets using the functional immunoassay for PAI-1 activity and the enzymelinked immunosorbent assay for PAL1 antigen.
SDS-polyacrylamide slab gels and buffers were prepared as described by Laemmli et alJO Samples were applied to gels composed of 10 cm resolving gels of 9% acrylamide and 2 cm stacking gels of 4% acrylamide, and subjected to electrophoresis at room temperature for 16 hours or until the dye reached the bottom of the gel.
Fibrin autography was performed as previously described.17 Briefly, fibrin-agar indicator films were prepared containing 1% agarose, fibrinogen (2.4 mg/ mL), human plasminogen (25 kg/mL), and a-thrombin (0.5 UlmL) (all final concentrations). The solution was mixed and poured onto prewarmed glass plates. After solidification of the fibrin-agar film, the SDS-gel that had been soaked for 1.5 hours in 2.5% Triton X-100 (Sigma) was layered onto the film and incubated in a humid chamber. Plates were read several times within the following hours of incubation at 37°C. For reverse fibrin autography, fibrin-agar indicator films were prepared as described above with the modification that the indicator films were supplemented with 0.05 U/mL urokinase, which converts plasminogen to plasmin, thus hydrolyzing the fibrin. Development of opaque, lysis-resistant zones in the otherwise clear indicator film showed PA1 activity. The gel and indicator were incubated in a moist chamber for 2 hours at 37°C and photographed in indirect light.
Quantitation of PAI-I activiy. PAI-1 activity was quantitated as previously d e~c r i b e d '~~~~ by using immobilized t-PA to bind active
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SDS-PAGE.

Direct and reverse fibrin autography.
For personal use only. on August 30, 2017. by guest www.bloodjournal.org From PAI-1 in a sample and the bound PAL1 immunologically detected by incubation with affinity-purified rabbit anti-PAI-1 (10 kg/mL) followed by 1251-goat antirabbit IgG (50,000 cpm/well). Two denaturants were used for activation of latent PAI-1. Samples were incubated in 0.1% SDS (1 hour, 37°C) followed by neutralization with a 50-fold excess of Triton X-100. Alternatively, samples (500 kL) were dialyzed against 4 mol/L guanidine-HCl(4 hours, 37"C), followed by dialysis against PBS. Platelet lysates were also depleted of active PAI-1 before activation with 4 mol/L guanidine. In this case, flat-bottom microtiter plates were precoated overnight at 4°C with 150 JLL t-PA (5 kg/mL in PBS). After a blocking step and two washes with PBS containing 0.01% Tween 20, platelet lysates (108 platelets/mL) were incubated in the wells (1 hour, 4°C). This process was repeated four times with each sample. Control samples were incubated simultaneously in wells that had been precoated overnight at 4°C with BSA (5 kg/mL).
Amidolytic assay for activity determination of purified porcine and humnn PAI-I. For standardizing PA-inhibitory activity of purified human and porcine PAI-1, an amidolytic assay was performed. In brief, increasing amounts of the purified inhibitor were added to a constant known amount of sct-PA. A standard curve was generated by the addition of increasing amounts of sct-PA to a buffer control. Residual PA activity was determined by reaction of the sample mixture with cyanogen bromide digest fragments of fibrinogen (American Diagnostica Inc), glu-plasminogen, and the chromogenic substrate, p-Val-Leu-Lys pNA (S-2251; Kabi Vitrum Inc, Franklin, OH). One unit of PAI-1 activity is defined as that amount needed to interact with and neutralize 1 IU t-PA activity in a standard plasminogen-based chromogenic assay.
Porcine PAI-1 antigen was quantitated using a double antibody immunoassay. Flat-bottom microtiter plates were precoated overnight (4°C) with affinity-purified rabbit antihuman PAL1 (10 kg/mL, 100 pL/well). At this and each subsequent step, the plates were washed with 0.01 mol/L TBS supplemented with 0.1% Triton X-100. The wells were then incubated with blotto (5% wt/vol skimmed milk powder in 10 mmol/L Tris, pH 7.5; 200 kL/well) for 2 hours to block any remaining reactive sites on the plastic. Test samples and standard curves of purified porcine PAI-1 were prepared in dilution buffer (blotto containing 0.5% Triton X-100). The diluted samples (100 kL) were incubated on the wells that had been precoated with antibody (1.5 hours, 37°C). Bound PAI-1 was detected by incubating the washed wells (1 hour, 37°C) with biotinylated affinitypurified rabbit antiserum to human PAI-1 (5 kg/mL, 100 FL/well) followed by incubation (30 minutes, 23°C) with streptavidine alkaline-phosphatase conjugate (Zymed Laboratories Inc, San Francisco, CA, 1:1,000 dilution in blotto, 100 p,L/well). After addition of the substrate para-nitrophenylphosphate, the resulting color change was measured at 405 nm over 10 minutes. The sensitivity and linear range of the calibration curve for porcine PAI-1 antigen was reduced by a factor of four in comparison with the dose-response curve produced in this assay using human PAL1 antigen (ie, linear range between 2 to 60 ng/mL for porcine PAI-1 v 0.5 to 15 ng/mL for human PAI-1). The specificity of the assay for human and porcine PAI-1 was confirmed by preabsorption of biotinylated rabbit antihuman PAI-1 using either human or porcine PAI-1 conjugated to Sepharose. No color development over background was observed using the appropriately absorbed antibodies.
Immunoprecipitation procedures. Protein A-Sepharose CL-4B (Pharmacia) was rehydrated in 0.14 mol/L NaC1, 10 mmol/L sodium phosphate buffer containing 0.1% BSA, 0.05% Tween 20, and 0.02% sodium azide (immunoprecipitation buffer, pH 7.4) according to Erickson et aL5 Rabbit antiserum against human PAI-1, human t-PA, and nonimmune rabbit serum (40 kL, respec-
Analysis of PAI-1 antigen.
tively) were incubated (15 minutes, 23°C) with the washed beads (30 kL packed beads representing 8 kg of Protein A-Sepharose). The beads were washed three times with immunoprecipitation buffer containing 0.5 mol/L NaCI, and platelet lysates (100 kL, representing 6 x lo* platelets) were added. The mixtures were incubated (1 hour, 23"C), centrifuged, and the resultant pellets were extracted with sample buffer. Both immunosupernatants and the extracts from the immunoprecipitates were fractionated by SDS-PAGE and analyzed by fibrin autography.
RESULTS
Active and denaturant-reactivatable PAI-1 in porcineplatelets.
To demonstrate that human t-PA reacts with porcine platelet PAI-1, we incubated human t-PA with porcine platelet lysates and subsequently analyzed the mixtures for the presence of high MI t-PA/inhibitor complexes by direct fibrin autography. Figure 1A indicates that human t-PA (MI 60 Kd, lane 1) interacts with a molecule in the porcine platelet lysates and forms high MI lytic zones (M, 110 Kd, lane 3). Moreover, these high MI lytic zones can be immunodepleted from the t-PA/platelet lysate incubation mixtures using antibodies to either human PAI-1 or human t-PA (lanes 4 and 5, respectively) and the high MI lytic zones can be recovered in the respective immunoprecipitates (lanes 7 and 8) . The ability of human t-PA to form complexes with porcine PAI-1 coupled with the observation that our rabbit antihuman PAI-1 preparation was able to recognize these complexes suggested that we should be able to quantitate the activity of porcine PAI-1 using a previously described functional immunoassay.21 This assay uses immobilized human t-PA to complex with solution phase PAI-1 and the bound PAI-1 molecules are subsequently quantitated using polyclonal antibodies to this inhibitor. Figure 1B indicates a comparison of the activity of PAI-1 in human platelets with the PAI-1 activity in porcine platelets using this system. Porcine platelet lysates exhibited approximately twofold more PAI-1 activity than human platelet lysates (3.7 f 0.4 and 1.7 2 0.3 U per 108 platelets, respectively).
Because SDS has been used by a number of investigators to activate the latent form of PAI-1,5-11 we used this assay to compare the ability of SDS to increase the activity of PAI-1 in porcine platelet lysates with the known effect of this denaturant to increase the activity of PAI-1 associated with human platelet lysates. Following a 1-hour treatment with 0.1% SDS, both porcine and human platelet lysates exhibited an approximately threefold increase in PAI-1 activity (10.8 f 3.0 and 3.8 2 0.5 U per lo8 platelets). To control for the effect of SDS in the functional assay, samples with SDS were first neutralized with a 50-fold excess of Triton X-100 and then mixed with the platelet lysate samples. PAI-1 activity in platelet lysates treated in this manner was found to be comparable with PAI-1 activity in untreated platelet lysates (Fig 1B) . In a separate series of experiments, freshly prepared porcine and human platelets were diluted to lo8 platelets/mL into a buffer containing 50 mmol/L arginine, pH 7.4, a known stabilizer of PAI-1 activity.19 Latent PAI-1 activity in these samples could still be detected following SDS-treatment similar to results shown in Fig 1B. For personal use only. on August 30, 2017. by guest www.bloodjournal.org (lanes 4 and 7) . To exclude the possibility that the SDS-induced increase in the activity of porcine platelet PAI-1 was mediated by an increase in the surface expression of certain epitopes on PAI-1, we attempted to confirm the presence of latent PAI-1 in porcine platelets by using an antibody-indcpendent technique. Figure 1C indicates that both porcine (lane 1) and human (lane 4) platelets exhibit an M, 50-Kd fibrinolytic inhibitory zone following fractionation by SDS-PAGE and analysis by reverse fibrin autography. Because these lysis-resistant zones may represent thc combined activity of both the active and latent form of a PAI, we pretreated the platelet lysates with an excess of t-PA to inactivate those PAIs in an active form. Subsequent analysis of the samples by SDS-PAGE is known to result in: (1) the separation of PAS, t-PA/PAI complexes, and PAIs based on molecular weight; and (2) the activation of latent PA IS.^ Figure 1C indicates that both porcine (lane 2) and human (lane 5 ) platelet lysates still exhibit prominent lysis-resistant zones in this technique, even though the samples had been pretreated with an excess of t-PA. In experiments not shown, preabsorption of the porcine and human platelet lysates with Sepharose Protein-A/anti-PAL1 beads resulted in the loss of the M, 50-Kd lysis-resistant zones. thus indicating that these zones represented PAI-1 present in the platelet lysates.
Because Fay and Oweni6 attempted to activate porcine platelet PAL1 by using 4 mol/L guanidine, we complemented the above experiments by comparing the ability of this denaturant to activate the latent form of PAL1 in both porcine and human platelets. Similar to the results obtained by treating porcine and human platelets with SDS (Fig lB) , a threefold to fivefold increase in the activity of PAI-1 was also observed by subsequent treatment with 4 mol/L guanidine ( Fig 1D) . Furthermore, immobilized t-PA was able to deplete active PAI-1 from the platelet extracts, and the latent form remaining in the absorbed extract could
For personal use only. on August 30, 2017. by guest www.bloodjournal.org From fin . be shown by activation with 4 mol/L guanidine. Finally, freshly isolated porcine platelets were lysed either with Triton X-100 (0.2%) or by sonication, and assayed before and after activation with 4 mol/L guanidine, yielding data similar to those shown in Fig 1D. Detection of active and denaturant-activatable PAI-1 during partial puri>cation of PAI-1 from porcine platelets. To investigate the differences between our observations and those of Fay and Owen,16 we performed the initial two steps of the purification procedure on an analytical scale. However, analysis of the resuspended ammonium sulfate precipitate (40% to 65%) showed primarily active PAI-1 because only a minor (ie, 1.3-fold) increase in PAI-1 activity was detected following treatment with 4 mol/L guanidine. Because of the known inability to detect latent PAI-1 in certain biological samples (eg, serum) with a high protein content: we attempted to detect latent PAI-1 in these resuspended ammonium sulfate precipitates by diluting the samples 10-fold before treatment with denaturants. Table 1 indicates that a threefold to fivefold increase in PAI-1 activity could be detected in the concentrated platelet pool (lo9 platelets/mL) and in the resuspended ammonium sulfate precipitates by using this protocol.
Chromatography of the resuspended ammonium sulfate precipitate over a molecular sieving column resulted in the elution of active PAI-1 before the elution of guanidineactivatable PAI-1 (Fig 2) . Fractions that represent the two peaks of PAI-1 activity were pooled separately (ie, fractions no. 49 to 51 and fractions no. 57 to 59 ; Fig 2 ) and assayed for PAI-1 activity before and after activation with 4 mol/L guanidine. PAI-1 activity in the active fractions (ie, no. 49 to 51) increased only about 1.3-fold following treatment with 4 mol/L guanidine, whereas little PAI-1 activity was detected in fractions no. 57 to 59 unless the samples were treated with a denaturant (Table 1 ). In addition, the partial purification of porcine PAI-1 was repeated using frozen and thawed platelet preparations, with similar results obtained with this material (data not shown).
DISCUSSION
In this report, we provide evidence that porcine platelets contain both active and latent PAI- an important feature of our analysis was the use of a functional immunoassay that uses antibodies to specifically quantitate the ability of PAI-1 to bind and to form complexes with t-PA? Using this assay, porcine platelets demonstrated approximately twofold higher PAI-1 activity levels than human platelets, which may reflect differences in PAI-1 content of platelets obtained from different species. The results of the functional immunoassay were confirmed by a standard semiquantitative assay for PAIS, routinely referred to as reverse fibrin autography. Prominent lysis-resistant zones, which could be immunodepleted using polyclonal antibodies to PAI-1, were still detected following activation with SDS even in those samples pretreated with a large excess of t-PA. Unfortunately, only small differences were detected between the t-PA-treated and untreated samples, suggesting that the activity of active Porcine platelets were extracted and chromatographed on a Sephacryl S-200 column as described. Aliquotsfrom the indicated steps were assayed Abbreviation: conc. concentration.
for PAL1 activity in the functional immunoassay either directly (active) or after treatment with 4 mollL guanidine.
For personal use only. on August 30, 2017. by guest www.bloodjournal.org From 2274 LANG ET AL PAI-1 may not be completely shown by this technique (ie, SDS-PAGE followed by reverse fibrin autography). In fact, the active form of human recombinant PAI-1 has been observed to be sensitive to SDS-induced denaturation (ie, a 65% decrease in active PAI-1 with 0.2% SDS-treatment), whereas detection of the latent form required activation with a denaturant. 22 The differences between our observation and those of Fay and OwenI6 were addressed by repeating the initial two steps of their purification procedure for porcine platelet PAI-1. A number of possibilities existed to account for the inability of these investigatorsI6 to detect the latent inhibitor in the crude platelet extracts. For example, Franke et aIz3 observed that the latent form of human recombinant PAI-1 is selectively precipitated using 35% ammonium sulfate. Differences between Fay and Owen's data and those of Franke et alZ3 may reflect species differences or the absence of oligosaccharides on the recombinant molecule. Another explanation arose from the reported inability of denaturants to activate latent PAI-1 in biological samples with a high protein content? As observed for latent PAI-1 in serum samples? we have found that a 10-fold dilution of the concentrated porcine platelet pool ( lo9 platelets/mL) or the resuspended ammonium sulfate precipitate extract was sufficient to permit the detection of guanidineactivatable PAI-1. Because active and latent human PAI-1 migrate quite differently on molecular sieving columns,lOJ1 we extended these observations to include the active and latent forms of the porcine molecule. Therefore, our data suggest that the differences in the migration of the two forms of PAI-1 during gel filtration accounts for the reported selective purification of active PAI-1 from porcine platelets. Finally, in the absence of sequence data for porcine PAI-1, the similar elution profile on a series of standard chromatographic columns does not indicate a structural basis for differences between the activity of porcine and human platelet PAI-1.
